Characteristics of candidemia in COVID-19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non-COVID-19 patients

Bircan Kayaaslan¹ | Fatma Eser¹ | Ayşe Kaya Kalem¹ | Zeynep Bilgic² | Dilek Asilturk² | Imran Hasanoglu¹ | Muge Ayhan² | Yasemin Tezer Tekce² | Deniz Erdem³ | Sema Turan³ | Ipek Mumcuoglu⁴ | Rahmet Guner¹

¹Department of Infectious Disease and Clinical Microbiology, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, Turkey
²Department of Infectious Disease and Clinical Microbiology, Ankara City Hospital, Ankara, Turkey
³Department of Intensive Care Unit, Ankara City Hospital, Ankara, Turkey
⁴Department of Medical Microbiology, Ankara City Hospital, Ankara, Turkey

Correspondence
Bircan Kayaaslan, Infectious Disease and Clinical Microbiology, Ankara Yildirim Beyazit University, Ankara City Hospital, Bilkent Street No. 1, Ankara 06800, Turkey.
Email: drbican@gmail.com

Abstract
Severe COVID-19 patients in ICU are at high risk for candidemia due to exposure to multiple risk factors for candidemia. We aimed to compare the incidence of candidemia in ICU patients with and without COVID-19, and to investigate epidemiologic and clinical characteristics of candidemia patients and risk factors for mortality in candidemia patients. This retrospective study was conducted in patients followed in the ICUs of Ankara City Hospital for 2 years, divided into pre-pandemic and pandemic periods. The incidence (event per 1000 patient-days) and epidemiology of candidemia and antifungal susceptibility were similar. Candidemia developed 2 weeks earlier in COVID-19 groups and resulted in higher mortality (92.5% vs. 79.4%, p = .005). One-third of candidemia patients died before receiving any antifungal treatment, and this rate was higher in the COVID-19 group. In multivariate logistic regression analysis, corticosteroid use, presence of sepsis and age older than 65 years were independent risk factors for mortality in candidemia patients. Candidemia with high mortality is a more serious problem for COVID-19 patients due to its increased incidence, earlier occurrence and a higher rate of mortality.

KEYWORDS
antifungal agents, Candida, candidemia, COVID-19, deep fungal infection, epidemiology, incidence, mortality risk factors, Thi steroids, ICU
1 | INTRODUCTION

*Candida* species are a significant cause of hospital-acquired bloodstream infections and may cause severe infections associated with prolonged hospital stays and high rates of mortality.1,2 The disease occurs particularly in patients who need intensive care and are immunocompromised. Exposure to broad-spectrum antibiotics and steroids, invasive procedures such as intravascular catheter and mechanical ventilation, haemodialysis, total parenteral nutrition and prior surgery – particularly abdominal surgery – are among high-risk factors for the development of candidemia.3

The global COVID-19 pandemic results in severe acute respiratory disease syndrome requiring intensive care unit (ICU) follow-up in some patients and consequently their exposure to various risk factors associated with candidemia.4 Demonstrating the benefit of corticosteroids in the treatment of severe COVID-19 in randomised controlled trials has resulted in a significant increase in the use of corticosteroids in hospitalised COVID-19 patients, particularly those followed in the ICU.5–7 Therefore, severe COVID-19 patients are exposed to corticosteroids in addition to many other risk factors for developing candidemia. Recent articles have drawn attention to the development of invasive fungal infections in critically ill COVID-19 patients and reported the increased incidence of candidemia in intensive care units during the pandemic period compared to the period before COVID-19.8–10 However, relatively few patients have been included in these studies. In the present study, we aimed to compare candidemia incidence rates in patients with and without COVID-19 hospitalised in ICUs during pre-pandemic and pandemic periods in a large patients’ series. Secondly, we aimed to evaluate the epidemiologic and clinical characteristics of candidemia patients with and without COVID-19, and to investigate risk factors for mortality.

2 | PATIENTS AND METHOD

This retrospective study was conducted in Ankara City Hospital, the main pandemic centre and a tertiary hospital in the capital. The authors confirm their adherence to the ethical policies of the journal, as noted on the journal’s author guidelines page. Ethical approval was obtained from Ankara City Hospital Ethical Committee 1. All patients older than 18 years followed with the diagnosis of candidemia in ICUs located in two buildings (neurology-orthopaedic and cardiovascular surgery) of the hospital with 6 hospital buildings between 1 March 2019 and 1 March 2021 were included in the study. Upon the detection of the first COVID-19 patient in Turkey in mid-March 2020, the hospital administration made a change in the planning of routine workflow and ICU use to meet the increasing COVID-19 patient burden. During the pandemic, some of these units served as the COVID-19 ICU where only COVID-19 patients were followed regardless of their underlying disease and organ-specific complications, while the remaining units continued to care for non-COVID-19 patients.

The study period was determined as 2 years, between 1 March 2019 and 1 March 2021, and divided into two periods. Between 1 March 2019 and 1 March 2021 was defined as the pre-pandemic period, and between 1 March 2020 and 1 March 2021 as the pandemic period. Patients followed-up in ICUs were divided into two groups as COVID-19 and non-COVID-19. The COVID-19 group included the patients followed in COVID-19 ICUs during the pandemic period with COVID-19 diagnosis, while non-COVID-19 group included those followed in ICUs during pre-pandemic and pandemic periods for reasons other than COVID-19. Total numbers of patient groups hospitalised in COVID-19 and non-COVID-19 ICUs in the defined periods and total patient-days were evaluated to calculate the incidence rates of candidemia. All patients with candidemia followed-up in COVID-19 and non-COVID-19 ICUs were retrospectively screened by using the hospital automation database system, and their data collected in a standardised patient form using medical records. Demographic and clinical characteristics including admission diagnoses, underlying medical conditions, comorbidities, risk factors for candidemia (concomitant bacteraemia, sepsis, central venous catheter, parenteral nutrition, gastrointestinal instrumentation/surgery, mechanical ventilation, prior antibiotic and corticosteroid uses), *Candida* colonisation index and Candida score were recorded in patients’ form.

The diagnosis of COVID-19 was made with polymerase chain reaction (PCR) for SARS-CoV-2 and/or the presence of typical findings for COVID-19 on computed tomography with a positive antibody test. Candidemia was identified as the detection of one or more *Candida* species in at least one blood culture in patients who have findings compatible with infection. Each patient was included only once in the study. Bact/Alert (bioMerieux) automated blood culture system was used for monitoring blood culture bottles. Yeasts were identified at species level by using VitekMS (bioMerieux) device and MALDI-TOF MS method. Sensitivity tests were evaluated with Vitek2 (bioMerieux) automated system. Candida colonisation index was calculated as the ratio of the number of distinct body sites colonised with *Candida* strain over the total number of distinct body sites cultures tested (threshold 0.5).11 Candida score was calculated as follows: multifocal *Candida* species colonisation (1 point), surgery (1 point), total parenteral nutrition (1 point), sepsis (2 points). Variables were encoded as 0 if it was absent and as valid points if it was present. The threshold was 2.5 points for high risk for candidemia.12

In order to evaluate whether there is a change in the incidence of candidemia during the pandemic period, we compared COVID-19 patients followed up in a one-year period (pandemic period) and non-COVID-19 patients followed up in two-year period (pre-pandemic and pandemic periods) in terms of candidemia incidence rate (candidemia episode per 1000 patient-days) and the percentages of candidemia (episode per 100 patients). We also compared candidemia cases with and without COVID-19 in terms of clinical characteristics, risk factors for candidemia, candidemia colonisation index, candidemia score, laboratory parameters on the day of
candidemia, Candida species, and antifungal susceptibilities, antifungal treatments and patients' outcomes including duration of ICU stay and mortality. Risk factors for mortality in patients with candidemia were investigated.

2.1 | Statistical analyses

Statistical analyses were performed with IBM SPSS V.20 software version and R Stats Package. We compared incidence rates of candidemia between patients with and without COVID-19 in ICU during the study periods using Poisson regression analysis. Descriptive statistics were presented as frequency and percentages for categorical variables, and medians with quartiles (interquartile range [IQR] 25th–75th percentile) for continuous variables. Categorical variables were compared using Chi-square test in parametric conditions. Student's t test and Mann Whitney U test were used in the comparison of continuous variables for normally distributed and non-normally distributed data, respectively. Multivariate logistic regression analysis was performed to investigate predictors of high mortality. A p-value of less than .05 was considered statistically significant.

3 | RESULTS

During the pandemic period, 2487 COVID-19 patients were followed up in COVID-19 ICUs for a total of 20,909 days. The number of non-COVID-19 patients admitted to ICUs during the pre-pandemic and pandemic period was 27,750 and the patients were followed for a total of 154,466 days. We observed a total of 236 candidemia episodes during the study period, 105 in COVID-19 patients and 131 in non-COVID-19 patients. Candidemia incidence rate was 2.16 (95% confidence interval 1.77–2.60) in COVID-19 group and higher than non-COVID-19 group (1.06, 95% confidence interval 0.89–0.125) (p < .001) (Table 1).

Non-COVID-19 patients had been particularly admitted to ICUs with the diagnoses of cardiovascular diseases (37), neurological diseases (32), respiratory system diseases (30), orthopaedic diseases (10), organ transplantation (3) and other varied reasons (19). Baseline demographic and clinical characteristics of candidemia cases with and without COVID-19 and risk factors for the development of candidemia are shown in detail in Table 2. Candidemia patients with COVID-19 had a higher rate of chronic pulmonary disease and a lower rate of heart failure than those without COVID-19 (p < .001, respectively). Risk factors for candidemia were similar among candidemia cases with and without COVID-19, except for gastrointestinal instrumentation or surgery, which was higher in non-COVID-19 patients (p < .02). Corticosteroid use was also detected higher in candidemia cases with COVID-19 (63.8%) compared to non-COVID-19 patients (9.9%) (p < .001). Prior or concomitant bacteraemia was detected in a total of 127 patients (53.8%), 35 of them were polymicrobial. The most frequent bacteria were
non-terminative basils (44) and staphylococci (44), followed by enterococci and *Klebsiella pneumonia*. Bacteraemia rates were similar among candidemia patients with and without COVID-19 patients (0 .38). There was no difference in candida colonisation index and candida score between candidemia cases with and without COVID-19 (p .85 and .14, respectively).

| Characteristics                                         | All patients (n = 236) | COVID-19 patients with candidemia (n = 105) | Non-COVID-19 patients with candidemia (n = 131) | p value |
|---------------------------------------------------------|------------------------|--------------------------------------------|-------------------------------------------------|---------|
| Age, median (IQR<sup>a</sup>)                          | 72 (18–94)             | 74 (60–81)                                 | 69 (58–81)                                      | .36     |
| Gender, male                                            | 135 (57.2)             | 55 (52.4)                                  | 80 (61.1)                                       | .18     |
| Any comorbidity                                         | 208 (88.1)             | 94 (89.5)                                  | 114 (87.0)                                      | .56     |
| Diabetes                                                | 78 (33.1)              | 38 (36.2)                                  | 40 (30.5)                                       | .36     |
| Hypertension                                            | 110 (46.6)             | 52 (49.5)                                  | 58 (44.3)                                       | .42     |
| Coronary artery disease                                 | 55 (23.3)              | 29 (27.6)                                  | 26 (19.8)                                       | .16     |
| Heart failure                                           | 40 (16.9)              | 13 (12.4)                                  | 27 (20.6)                                       | .09     |
| Chronic pulmonary disease                               | 36 (15.3)              | 23 (22.1)                                  | 13 (9.9)                                        | .01     |
| Chronic renal disease                                   | 17 (7.2)               | 10 (9.5)                                   | 7 (5.3)                                         | .2      |
| Malignity                                               | 27 (11.4)              | 11 (10.5)                                  | 16 (12.2)                                       | .67     |
| Immunosuppression                                       | 14 (5.9)               | 6 (5.7)                                    | 8 (6.1)                                         | .89     |
| Cerebrovascular events                                  | 19 (8.1)               | 5 (4.8)                                    | 14 (10.7)                                       | .88     |
| Mechanical ventilation                                  | 202 (85.6)             | 92 (87.6)                                  | 110 (84.0)                                      | .43     |
| Duration of intubation                                  | 5 (1–15)               | 5 (1–11.5)                                 | 5 (1–22)                                        | .27     |
| Sepsis                                                  | 144 (61.0)             | 64 (61.0)                                  | 80 (61.1)                                       | .98     |
| Central venous catheter                                 | 227 (96.2)             | 103 (98.1)                                 | 127 (94.7)                                      | .17     |
| Total parenteral nutrition                              | 73 (30.9)              | 26 (24.8)                                  | 47 (35.9)                                       | .66     |
| Gastrointestinal instrumentation or surgery             | 23 (9.7)               | 5 (4.8)                                    | 18 (13.7)                                       | .02     |
| Presence of *Candida* spp in urine sample               | 105 (44.5)             | 47 (44.8)                                  | 58 (44.3)                                       | .94     |
| Presence of *Candida* spp in DTA<sup>b</sup> sample     | 78 (33.1)              | 32 (30.5)                                  | 46 (35.5)                                       | .45     |
| Multifocal candida colonisation                          | 59 (25.0)              | 24 (22.9)                                  | 35 (26.7)                                       | .49     |
| Candida colonisation index<sup>c</sup>                  |                        |                                            |                                                |         |
| ≤0.5                                                    | 111 (47)               | 50 (47.6)                                  | 61 (46.6)                                       | .85     |
| ≥0.6                                                    | 125 (53)               | 55 (52.4)                                  | 70 (53.4)                                       |         |
| Candida score<sup>d</sup>                               |                        |                                            |                                                |         |
| ≤2 point                                                | 152 (64.4)             | 73 (69.5)                                  | 79 (60.3)                                       | .14     |
| ≥3 point                                                | 84 (35.6)              | 32 (30.5)                                  | 52 (39.7)                                       |         |
| Presence of prior bacteraemia<sup>e</sup>              | 127 (53.8)             | 52 (49.5)                                  | 75 (57.3)                                       | .38     |
| Prior use of extended spectrum antibiotic               | 228 (96.6)             | 99 (94.3)                                  | 129 (98.5)                                      | .77     |
| Prior use of corticosteroid                             | 80 (33.9)              | 67 (63.8)                                  | 13 (9.9)                                        | <.001   |

Note: Data are presented as n (%) unless noted otherwise.

<sup>a</sup>IQR, Interquartile range (25% and 75%).

<sup>b</sup>DTA, Deep tracheal aspirate.

<sup>c</sup>Candida colonisation index: Ratio of the number of distinct body sites colonised with Candida strain/the total number of distinct body sites cultures tested. Threshold 0.5.

<sup>d</sup>Candida score: The total score obtained from the following: Multifocal Candida species colonisation (1 point), surgery (1 point), total parenteral nutrition (1 point), sepsis (2 points). Threshold 2.5.

<sup>e</sup>Causative microorganisms in blood cultures (162): Coagulase-negative staphylococci (44), non-fermentative gram-negative bacillus (42), *Klebsiella pneumonia* (26), *Enterococcus spp* (24), *Staphylococcus aureus* (9), *Escherichia coli* (7) and others (10).
White blood cell count, neutrophil count, urea, creatinine, aspartate aminotransferase, alanine aminotransferase and procalcitonin levels measured on the day of candidemia were detected significantly higher in candidemia patients with COVID-19 than cases without COVID-19. Laboratory parameters of candidemia patients in both groups on the day of candidemia are shown in detail in Table 3. Duration from ICU admission to candidemia was shorter in COVID-19 patients (13 days [IQR 8–24]) than non-COVID-19 cases (27 days [IQR 13–45]) (p < .001). Antifungal therapy was given to only 63.1% of candidemia patients, and this rate was significantly lower in COVID-19 patients (53.2%) compared to non-COVID-19 patients (71.7%) (p = .003), as shown in Table 4.

*Candida albicans* was the most common agent of candidemia and detected in 40.0% of COVID-19 and 47.3% of non-COVID-19 patients. No difference was found between COVID-19 and non-COVID-19 groups in terms of candida type and antifungal susceptibilities (Table 4). The antifungal agent to which Candida species were most susceptible was micafungin with a susceptibility rate of 94.1%, followed by amphotericin B (93.3%). Candidemia developed earlier in COVID-19 patients (median 13 days) than non-COVID-19 patients (median 27 days) (p < .001). Only 53.2% of COVID-19 patients with candidemia were able to receive antifungal therapy, and this rate was statistically significantly lower compared to non-COVID-19 group with candidemia (71.7%) (p = .003). The most preferred antifungal agent was anidulafungin in both groups. Duration of antifungal treatment was shorter in COVID-19 patients compared to non-COVID-19 patients (p = .002).

Duration of ICU stay was significantly shorter in COVID-19 patients (23 days) than non-COVID-19 patients (45 days) (p < .001). Mortality rate was high (85.2%) in all patients with candidemia; it was significantly higher in COVID-19 patients than non-COVID-19 patients (92.5% vs. 79.4%, p = .5). In multivariate logistic regression analysis, corticosteroid treatment, presence of sepsis and age older than 65 years were found to be independent risk factors for mortality (Table 5).

| Laboratory parameters on the day of candidemia, median (IQR) | All patients (n = 236) | COVID-19 patients with candidemia (n = 105) | Non-COVID-19 patients with candidemia (n = 131) | p value |
|---------------------------------------------------------------|------------------------|-------------------------------------------|-----------------------------------------------|--------|
| White blood cell, cells ×10⁹/L                                | 11.6 (7.9–18.4)        | 13.5 (8.9–22.9)                           | 11.9 (7.3–15.0)                               | .001   |
| Neutrophil count, cells ×10⁹/L                                | 9.7 (6.4–15.9)         | 11.8 (8.0–22.0)                           | 8.5 (6.0–11.0)                                | <.001  |
| Platelet count, cells ×10⁹/L                                  | 200 (117–301)          | 196 (102–298)                             | 316 (186–3760)                                | .23    |
| C-reactive protein, g/L                                       | 0.13 (0.064–0.189)     | 0.126 (0.053–0.199)                       | 0.133 (0.017–0.186)                          | .78    |
| Procalcitonin, μg/ml                                          | 1.0 (0.3–5.1)          | 1.98 (0.36–7.7)                           | 0.85 (0.14–3.2)                               | .006   |
| Urea, mg/dl                                                   | 86.5 (48–157)          | 122 (56–196)                              | 83 (36–128)                                  | .002   |
| Creatinine, mg/dl                                             | 1.1 (0.6–2.5)          | 1.6 (0.7–3.4)                             | 1.0 (0.5–3.7)                                | .007   |
| Aspartate transaminase, U/L                                   | 47 (28–98)             | 73 (37–153)                               | 50 (32–90)                                   | .030   |
| Alanine transaminase, U/L                                     | 32 (17–59)             | 44 (26–87)                                | 32 (22–59)                                   | .002   |
| D-dimer, mg/L                                                 | 4.5 (2.5–10.8)         | 4.3 (2.2–10.2)                            | 7.0 (3.9–14.0)                                | .14    |

|IQR, Interquartile range (25% and 75%).

4 | DISCUSSION

Patients with severe COVID-19, particularly those followed in the ICU, are at risk for developing candidemia. Most of the risk factors for candidemia such as the use of broad-spectrum antibiotics and corticosteroids, invasive procedures (central venous catheter, mechanical ventilation and haemodialysis), surgical procedures become an inevitable necessity in these patients during the follow-up. Recent studies reported an extra increase in candidemia cases in patients with COVID-19 compared to non-COVID-19 patients; however, the number of patients reported in these studies is relatively small.⁸–¹⁰ A total of 41 episodes of candidemia were included in the study of Nucci et al, and a total of 72 candidemia episodes in the study of Mastrangelo et al.⁹

In this study, we evaluated a large number of patients who were followed up in COVID-19 and non-COVID-19 ICUs for 2 years (pre-pandemic and pandemic periods) and clearly demonstrated an approximately 2-fold increase in the incidence of candidemia in patients with COVID-19 compared to those who did not have COVID-19. Similarly, in the study by Mastrangelo et al,⁹ the incidence of candidemia (cases per 10,000 patient-days) in patients with COVID-19 was 10.97 (6.79–16.76), while it was 1.48 (1.10–1.95) in non-COVID-19 historical cohort patients (p < .001). Riche et al.¹⁰ also reported a marked increase (10-fold) in the incidence of candidemia in COVID-19 patients compared to those who did not have COVID-19 (1.43 vs. 10.23 in one hospital and 1.15 vs. 11.83 in another hospital per 1000 patient-days, p < .001). The incidence of candidemia may differ between centres depending on the characteristics of the centres and patients (eg whether it is a specific branch hospital), the numbers of blood cultures taken from the patients, and laboratory workouts. However, our study and other reports clearly revealed that COVID-19 patients have an additional risk for the development of candidemia compared to patients followed for non-COVID-19 reasons. This increase is, in fact, an expected result due to the increased exposure of COVID-19 patients to risk factors associated with candidemia, such as the need for corticosteroid use in severe disease, the...
characteristic multisystem involvement of the disease and the increased use of broad-spectrum antibiotics in their treatment due to complicated clinical and laboratory conditions. The widespread use of broad-spectrum antibacterial agents in critically ill patients leads to the suppression of normal flora and development of candida colonization in the gut, and eventually translocation of candida to the bloodstream system.\textsuperscript{3,4} Similarly, corticosteroids enhance the adhesion of Candida species to the epithelial cells, their growth in the gut, and translocation from the gastrointestinal tract to the bloodstream (shown in vitro studies). In addition, corticosteroids affect negatively almost every cell type in the immune system in many complicated ways and enhance cellular immunodeficiency.\textsuperscript{10,13}

### TABLE 4 Candida species, antifungal susceptibilities, antifungal treatments and clinical outcomes of candidemia patients with and without COVID-19

| Characteristics | All patients\textsuperscript{(n = 236)} | COVID-19\textsuperscript{(n = 105)} | Non-COVID-19 \(n = 131\) | \(p\)-value |
|-----------------|------------------------------------------|---------------------------------|----------------------------|------------|
| **Candida species** |                                          |                                 |                            |            |
| C. albicans     | 104 (44.1)                               | 42 (40.0)                       | 62 (47.3)                  | >.05       |
| C. parapsilosis | 58 (24.5)                                | 20 (19.0)                       | 38 (29.0)                  | >.05       |
| C. glabrata     | 33 (14.0)                                | 19 (18.1)                       | 14 (10.7)                  | >.05       |
| C. tropicalis   | 22 (9.3)                                 | 13 (12.4)                       | 9 (6.9)                    | >.05       |
| Others          | 19 (8.1)                                 | 11 (10.5)                       | 8 (6.1)                    | >.05       |
| **Antifungal susceptibilities** |                                       |                                 |                            |            |
| Fluconazole     | 161 (68.2)                               | 73 (69.5)                       | 88 (67.2)                  | .82        |
| Voriconazol     | 167 (70.8)                               | 75 (71.4)                       | 92 (70.8)                  | .17        |
| Caspofungin     | 191 (80.9)                               | 81 (77.1)                       | 110 (84.0)                 | .37        |
| Miacfungin      | 222 (94.1)                               | 100 (95.2)                      | 122 (93.1)                 | .14        |
| Flucytosine     | 220 (93.2)                               | 100 (95.2)                      | 120 (91.6)                 | .54        |
| Amphotericin B  | 218 (93.3)                               | 98 (91.6)                       | 120 (92.4)                 | .62        |
| **Time (days) from ICU admission to candidemia, median (IQR)\textsuperscript{a}** | 19.5 (9–33) | 13 (8–24) | 27 (13–45) | <.001 |
| **Number of patients received antifungal treatment** | 149 (63.1) | 55 (53.2) | 94 (71.7) | .003 |
| **Number of patients received antifungal treatment for more than 4 days** | 125 (53) | 43 (41.0) | 82 (62.6) | .001 |
| **Time (h) from culture positivity to initiation of antifungal treatment, median (IQR)** | 59 (24–72) | 60 (24–72) | 58 (24–72) | .10 |
| **Duration (days) of antifungal treatment in patients received antifungal treatment, median (IQR)** | 12 (5–20) | 7 (4–18) | 16 (7–21) | .002 |
| **Antifungal treatment** |                                       |                                 |                            | .052      |
| Anidulafungin   | 86 (36.6)                                | 31 (29.5)                       | 55 (42.3)                  |           |
| Caspofungin     | 6 (2.6)                                  | 3 (2.9)                         | 3 (2.3)                    |           |
| Miacfungin      | 25 (10.6)                                | 7 (6.7)                         | 18 (13.8)                  |           |
| Fluconazole     | 23 (9.9)                                 | 11 (10.5)                       | 12 (9.2)                   |           |
| Voriconazol     | 4 (1.7)                                  | 2 (1.9)                         | 2 (1.5)                    |           |
| Amphotericin B  | 5 (2.1)                                  | 1 (1.0)                         | 4 (3.1)                    |           |
| No antifungal drug treatment | 87 (36.9) | 50 (46.8) | 37 (28.3) |           |
| **Vegetation on echocardiography\textsuperscript{b}** | 5/59 (8.5) | 0/9 (0) | 5/50 (10.0) | <.001 |
| **Endophthalmitis on funduscopic examination\textsuperscript{b}** | 2/20 (10.0) | 0/3 (0) | 2/17 (11.8) | .019 |
| Abnormal findings on abdominal CT\textsuperscript{b,c} | 1/20 (5.0) | 0/5 (0) | 1/15 (6.7) | .16 |
| **Duration (days) of ICU stay, median (IQR)** | 33 (17–55) | 23 (12–37) | 45 (26–70) | <.001 |
| **Death** | 201 (85.2) | 97 (92.5) | 104 (79.4) | .005 |
| **28-day mortality** | 179 (75.8) | 90 (87.5) | 89 (67.9) | .002 |

Note: Data are presented as \(n\) (%) unless noted otherwise.
\(a\)IQR, Interquartile range (25% and 75%).
\(b\)Echocardiography, funduscopic examination and abdominal CT were performed in 59, 20 and 20 patients respectively.
\(c\)CT, Computed tomography (infarction in spleen).
Corticosteroids are recommended in the treatment of critically ill patients who need oxygen or ventilation support since a reduced mortality was demonstrated with corticosteroid use compared to standard care or placebo in patients with severe COVID-19 in randomised controlled studies. However, besides their benefits, it has long been known that the risk of developing candidemia increases with corticosteroid use. In the report by Riché et al., although a small number of patients were included, it was shown that all COVID-19-associated candidemia patients received prior corticosteroid therapy. Similarly, we detected dramatically higher rates of corticosteroid use in candidemia patients with COVID-19 compared to those without COVID-19.

One of the remarkable results of the present study is that candidemia developed in the earlier periods of ICU admission and not covering candidemia and poor survival in patients with candidemia despite its benefits.

Another notable result of our study is that one-third of all patients with candidemia in the study had died before receiving any antifungal treatment, and this rate was higher in COVID-19 group. Some of the remaining patients with COVID-19 were able to receive antifungal treatment for shorter than proper treatment duration. These results show that candidemia does not come to mind in the early period of infection in ICU patients, especially COVID-19 patients.

Candida types, antifungal susceptibility and treatment choice were not different between COVID-19 and non-COVID-19 groups. Candida albicans was the most frequent type in the present study and previous studies. Mastrangelo et al also reported similar rates of non-albicans candidemia between groups in a total of 72 candidemia patients. Previous other studies had even fewer patients. Majority of the patients were given anidulafungin, micafungin and fluconazole. All organ involvements were in the non-COVID group, but comprehensive diagnostic intervention had been performed on more patients in this group compared to COVID-19 group. Hepatic and renal function tests, and inflammation markers were higher in COVID-19 patients than non-COVID-19 patients. This may be due to the multisystemic characteristic of COVID-19 or the cause of the cytokine storm that requires ICU follow-up, especially in the severe form. Severe COVID-19 and candidemia are both life-threatening infections, with mortality rates reported at over 50% in patients with candidemia and 49% in critical COVID-19.

### Table 5: Multivariate logistic regression analysis of the risk factors for mortality

| Variables                        | Candidemia Alive (n = 35) | Candidemia Deceased (n = 201) | p-value | Odds ratio (95% CI) | p-value |
|----------------------------------|---------------------------|-------------------------------|---------|--------------------|---------|
| Age ≥65 years                    | 12 (34.3)                 | 139 (69.2)                    | <.001   | 5.6 (2.3–13.4)     | <.001   |
| Admission diagnosis, COVID-19    | 8 (22.9)                  | 97 (48.3)                     | .005    |                    |         |
| Antifungal treatment over than 3 days | 27 (77.1)              | 98 (48.8)                     | .002    |                    |         |
| Prior corticosteroid use         | 6 (17.5)                  | 77 (36.8)                     | .023    | 4.4 (1.5–12.6)     | .006    |
| Presence of sepsis               | 8 (22.9)                  | 136 (67.7)                    | <.001   | 7.6 (3.1–19.0)     | <.001   |
| Candida species, non-albicans    | 26 (74.5)                 | 105 (52.2)                    | .015    |                    |         |

CI, Confidence interval.

In another large series study, corticosteroid use differed between surviving and deceased patients, but was not an independent risk factor in multivariate analysis. Appropriate and non-delayed antifungal therapy is crucial for the treatment of candidemia. This study supported the results of previous studies. We also demonstrated that corticosteroid treatment is a mortality-associated factor in patients with candidemia despite its benefits in severe COVID-19 patients. In a large series with 842 patients with candidemia, corticosteroid use was found to be associated with treatment failure and poor survival. In another large series study, corticosteroid use differed between surviving and deceased patients, but was not an independent risk factor in multivariate analysis. Appropriate and non-delayed antifungal therapy is crucial for the treatment of candidemia. This study, some of the patients were unable to receive any antifungal agents, and some had received for 3 days or shorter. However, we did not demonstrate an independent association between short treatment duration and mortality in multivariate analysis. Delaying antifungal treatment until the obtainment of positive blood culture was reported as an independent risk factor for high mortality.
There are some limitations in the present study. The conducting of the study in two of the six specified buildings of the hospital (neurology-orthopaedic and cardiovascular surgery buildings) may have led to the selection of a special patient population among non-COVID-19 patients. However, patient selection related to specific branches had to get up during the pandemic periods for COVID-19 and non-COVID-19 patients and had relatively fewer negative effects on patient population. Another important limitation was that we could not investigate specific risk factors for the development of candidemia in COVID-19 patients because of the difficulty of including COVID-19 patients without candidemia. The other limitation is the retrospective character of the study, as data obtained from patient files may be incomplete or incorrect.

In conclusion, we detected an increased incidence of candidemia in COVID-19 patients compared to non-COVID-19 group followed in pre-pandemic and pandemic periods. Clinical characteristics were substantially similar in two groups. The most remarkable difference between groups was prior corticosteroid exposure. While the majority of COVID-19 patients were given corticosteroid therapy, only a small proportion of non-COVID-19 patients received it. The possible collateral damage of corticosteroid therapy, such as severe candida infection, should not be forgotten in the management and treatment selection of ICU patients, especially those diagnosed with COVID-19. Our study showed that candidemia may develop earlier, approximately within 2 weeks, in patients hospitalised in the ICU with COVID-19 compared to those hospitalised for other reasons and cause high mortality with a rate of 92.5%. Corticosteroid use, presence of sepsis and advanced age were independent risk factors for mortality in patients with candidemia. Candidemia with high mortality rates should always be kept in mind during the follow-up of ICU patients, even in the early period.

CONFLICT OF INTEREST
The authors have no conflicts of interest to declare.

AUTHOR CONTRIBUTION
Bircan Kayaaslan: Conceptualization (lead); Formal analysis (lead); Investigation (lead); Methodology (lead); Writing-original draft (lead); Writing-review & editing (lead). Fatma Eser: Formal analysis (supporting). Ayse Kaya Kalem: Investigation (supporting); Writing-review & editing (equal). Zeynep Bilgic: Investigation (equal). Dilek Asilturk: Investigation (equal). Imran Hasanoğlu: Writing-review & editing (supporting). Muge Ayhan: Investigation (lead). Yasemin Tezer Tekce: Data curation (supporting). Deniz Erdem: Formal analysis (lead). Sema Turan: Writing-review & editing (lead). İpek Mumcuoglu: Formal analysis (equal). Rahmet Guner: Conceptualization (supporting); Methodology (supporting); Writing-review & editing (supporting).

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

ORCID
Bircan Kayaaslan https://orcid.org/0000-0001-5225-8319

REFERENCES
1. Bassetti M, Rigi E, Ansaldi F, et al. A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med. 2014;40(6):839-845.
2. Lodde I, Stamou S, Sanchez J. Hospital-acquired infections. Surg Clin North Am. 2012;92(1):65-77.
3. Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med. 2015;373(15):1445-1456.
4. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242.
5. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693-704.
6. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The CoDER randomized clinical trial. JAMA. 2020;324(13):1307-1316.
7. Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324(13):1317-1329.
8. Nucci M, Barreiros G, Guimarães LF, Deriquehem VAS, Castêlheiras AC, Nourê SA. Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic. Mycoses. 2021;64(2):152-156.
9. Mastrangelo A, Germinario BN, Ferrante M, et al. Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls [published online ahead of print. 2020 Oct 30]. Clin Infect Dis. 2020;ciaa1194.
10. Riche CVW, Cassol R, Pasqualotto AC. Is the frequency of Candidaemia increasing in COVID-19 patients receiving corticosteroids? J Fungi (Basel). 2020;6(4):286.
11. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220(6):751-758.
12. León C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006;34(3):720-737.
13. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet. 2003;362(9398):1828-1838.
14. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330-1341.
15. Al-Hatmi AMS, Mohsin J, Al-Huraizi A, Khamis F. COVID-19 associated invasive candidiasis. J Infect. 2021;82(2):e45-e46.
16. Arastehfar A, Carvalho A, Nguyen MH, et al. COVID-19-associated candidiasis (CAC): an underestimated complication in the absence of immunological predispositions? J Fungi (Basel). 2020;6(4):211. Published 2020 Oct 8.
17. Ferrada MA, Quartin AA, Kett DH, Morris MI. Candidemia in the critically ill: initial therapy and outcome in mechanically ventilated patients. BMC Anesthesiol. 2013;13(1):37.
18. Bassetti M, Merelli M, Righi E, et al. Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol. 2013;51(12):4167-4172.
19. Kato H, Yoshimura Y, Suido Y, et al. Mortality and risk factor analysis for Candida blood stream infection: a multicenter study. J Infect Chemother. 2019;25(5):341-345.

20. Guimarães T, Nucci M, Mendonça JS, et al. Epidemiology and predictors of a poor outcome in elderly patients with candidemia. Int J Infect Dis. 2012;16(6):e442-e447.

21. Nucci M, Anaissie E, Betts RF, et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis. 2010;51(3):295-303.

22. Motta FA, Dalla-Costa LM, Muro MD, et al. Risk factors for candidemia mortality in hospitalized children. J Pediatr (Rio J). 2017;93(2):165-171.

23. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49(9):3640-3645.

How to cite this article: Kayaaslan B, Eser F, Kaya Kalem A, et al. Characteristics of candidemia in COVID-19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non-COVID-19 patients. Mycoses. 2021;00:1–9. https://doi.org/10.1111/myc.13332